
|Videos|July 13, 2020
Radioiodine Refractory Differentiated Thyroid Carcinoma
Author(s)Targeted Oncology
A key opinion leader discusses the evolving treatment landscape for radioiodine refractory differentiated thyroid carcinoma, with special consideration of the phase 3 SELECT trial.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
4
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
5





































